FSHB -211 G>T 是育龄女性生殖生理与健康的主要遗传调节因子
在169名月经规律健康女性和186名不孕夫妇女性伴侣中,检测 FSHB -211 G>T、FSHR c.2039 A>G 和 FSHR -29 G>A 与血清 FSH、LH、AMH 及月经参数和不孕风险的关联;仅 FSHB -211 G>T 的 T 等位基因与血清 FSH 和 LH 升高相关,且 T 等位基因在不孕症患者中富集。
要点
- FSHB -211 G>T 的 T 等位基因与血清 FSH 和 LH 升高相关(FSH 效应 0.80 IU/L,P=1.2×10-3;LH 效应 1.58 IU/L,P=1.8×10-8)。
- 特发性不孕女性 T 等位基因频率为 23.6%,对照组为 12.4%(P=8.9×10-3)。
- FSHR -29 G>A 与所分析生殖参数均无关联。
核心结论
- 仅 FSHB -211 G>T 变异是月经规律健康女性和女性不孕患者血清促性腺激素水平的主要遗传决定因素,且 T 等位基因在不孕症患者中富集。
研究设计与样本
- 在爱沙尼亚塔尔图大学医院妇女诊所 HAPPY PREGNANCY 研究(2013-2015年)中招募两组独立临床队列:无已知生育问题的月经规律健康女性(n=169,27.6±6.1岁)和不孕夫妇的女性伴侣(n=186,32.4±4.7岁)。
- 在月经周期卵泡期(第2-6天)测量血清 FSH、LH 和 AMH,采用 PCR 和 Taqman 等位基因区分法对三个单核苷酸多态性(SNP)进行基因分型。
- 采用加性和隐性模型线性回归评估变异对激素和月经周期数据的影响,校正年龄、BMI 和吸烟状态;两组结果采用固定效应模型进行荟萃分析。
- 采用限制性最大似然分析估计所测遗传变异可解释的生殖参数总表型方差比例;病例对照分析采用 Fisher 精确检验和校正年龄、BMI 和吸烟状态的逻辑回归检验不孕状态的遗传关联。
主要发现
- 在两个研究组中,FSHB -211 G>T 的 T 等位基因均与血清 FSH 和 LH 水平显著升高相关;荟萃分析(加性遗传模型)经 Bonferroni 多重检验校正后仍显著:FSH,T 等位基因效应 0.80 IU/L,P=1.2×10-3;LH,1.58 IU/L,P=1.8×10-8。
- FSHB -211 G>T 的 T 等位基因对循环 LH 的更显著效应被确定为 LH/FSH 比值升高的驱动因素(荟萃分析,P=4.7×10-3)。
- 在健康女性中,FSHB -211 G>T 变异估计分别解释所测血清 FSH 和 LH 水平总方差的 3.5% 和 7.1%;在不孕患者中相应数值分别为 1.6% 和 10.5%。
- 与对照组相比,特发性不孕女性的 T 等位基因频率翻倍(23.6% 对 12.4%;P=8.9×10-3),TT 纯合子超出 3 倍以上(5.6% 对 1.8%;P=3.5×10-2)。
- FSHR c.2039 A>G 的唯一关联是在月经规律健康女性中与血清 FSH 水平相关,解释总参数方差的 3.9%(G 等位基因效应 0.56 IU/L,P=4.6×10-3);在健康育龄女性研究组中,FSHB -211 T 等位基因携带者合并 FSHR c.2039 GG 基因型者血清 FSH 水平最高(中位数 7.7 IU/L),而 FSHB -211 GG 合并 FSHR c.2039 AA 纯合子者激素浓度最低(中位数 5.8 IU/L,P=9.6×10-3)。
临床怎么用
- 作者提出,如同在男性中一样,在女性中 FSHB -211 G>T 也是循环促性腺激素的关键遗传调节因子,可能对生殖生理产生多种下游效应。
- 作者认为,FSHB -211 G>T 在生育诊所可能具有诊断价值,用于检测遗传性基础 FSH 和 LH 水平升高的女性患者。
局限性
- 样本量小以及设计涉及两个生殖史不同的临床组,可能限制了复制全基因组关联研究最初报告的初潮年龄和月经周期长度关联的能力。
- 样本量小也可能影响估计所测变异对所测促性腺激素浓度总表型方差贡献的准确性。
- 月经规律健康女性组作为对照估计所分析遗传变异对个体生育潜能真实效应存在局限性,因为招募策略主要针对较年轻女性,她们可能尚未计划在此年龄生育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are the genetic variants FSHB -211 G>T (rs10835638), FSHR c.2039 A>G (Asn680Ser, rs6166) and FSHR -29 G>A (rs1394205) associated with serum FSH, LH and anti-Müllerian hormone (AMH) levels in reproductive age women, their menstrual cycle parameters and risk of infertility? SUMMARY ANSWER: Only the FSHB -211 G>T variant was a major genetic determinant of serum gonadotropin levels in both, eumenorrheic healthy women and female infertility patients, and the T-allele carrier status was enriched among idiopathic infertility cases. WHAT IS KNOWN ALREADY: There are accumulating data on common genetic variants modulating reproductive parameters and fertility potential. FSHB -211 G>T represents the strongest acknowledged genetic factor contributing to male circulating gonadotropins levels. Respective data in women are limited and the two previously published studies have reached conflicting results. In addition, previous studies have consistently associated FSHR c.2039 A>G (but not FSHR -29 G>A) with female serum FSH level. STUDY DESIGN, SIZE, DURATION: The study aimed to test robust and clinically meaningful genetic effects (if present) of the FSHB -211 G>T, FSHR c.2039 A>G and FSHR -29 G>A variants on female basal FSH, LH and AMH levels, and linked reproductive parameters. Genetic association testing was performed in two independent and clinically different study groups (i) eumenorrheic healthy women without known fertility problems (n = 169; 27.6 ± 6.1 years) and (ii) female partners of infertile couples (n = 186; 32.4 ± 4.7 years). The study groups were compared for allelic and genotypic distributions of the analysed variants. PARTICIPANTS/MATERIALS, SETTING, METHODS: All participants were recruited during the HAPPY PREGNANCY study (2013-2015) at the Women's Clinic, Tartu University Hospital, Estonia. Serum FSH, LH and AMH were measured in the follicular phase (Days 2-6) of the menstrual cycle. All three single nucleotide polymorphisms (SNPs) were genotyped by PCR and Taqman allelic discrimination assay. The effect of the analysed variants on hormonal measurements and menstrual cycle data was assessed using linear regression under additive and recessive models adjusted by age, BMI and smoking status. Results of the two subgroups were combined in a meta-analysis applying the fixed effects model. Restricted maximum likelihood analysis was applied to estimate the proportion of total phenotypic variance of analysed reproductive parameters, explainable by the tested genetic variants. In case-control analysis, genetic association with infertility status was tested using Fisher's exact test and logistic regression adjusted by age, BMI and smoking status. MAIN RESULTS AND THE ROLE OF CHANCE: In both study groups, T-allele of the FSHB -211 G>T was associated with significantly higher serum levels of FSH and LH. Results of the meta-analysis (additive genetic model) remained significant after Bonferroni correction for multiple testing: FSH, T-allele effect 0.80 IU/L, P = 1.2 × 10-3; LH, 1.58 IU/L, P = 1.8×10-8. A more pronounced effect of T-allele of the FSHB -211 G>T on circulating LH was identified as a driving factor to increased LH/FSH ratio (meta-analysis, P = 4.7 × 10-3). In healthy women, the FSHB -211 G>T variant was estimated to explain 3.5 and 7.1% of the total variance of the measured serum FSH and LH levels, respectively. The corresponding numbers for the infertility patients were 1.6 and 10.5%. Women with idiopathic infertility compared to controls exhibited a doubled T-allele frequency (23.6 versus 12.4%; P = 8.9 × 10-3) and a >3-fold excess of TT homozygotes (5.6 versus 1.8%; P = 3.5 × 10-2). The only association of the FSHR c.2039 A>G was detected with serum FSH levels in eumenorrheic healthy women, explaining 3.9% of the total parameter variance (G-allele effect 0.56 IU/L, P = 4.6 × 10-3). In the study group of healthy reproductive age women, the highest serum FSH levels were detected among the FSHB -211 T-allele carriers with the FSHR c.2039 GG-genotype (median 7.7 IU/L). In contrast, the lowest hormone concentrations were measured for the women carrying the combination of the FSHB -211 GG- and the FSHR c.2039 AA-homozygosity (median 5.8 IU/L, P = 9.6 × 10-3). None of the analysed reproductive parameters was associated with the FSHR -29 G>A variant. In our study groups, the tested polymorphisms did not reach significant associations with serum AMH measurements, menstrual cycle length or age at menarche. LIMITATIONS, REASONS FOR CAUTION: Small sample size and the design involving two clinical groups with different reproductive histories may have limited the capacity to replicate the associations with the age at menarche and length of menstrual cycle, initially reported in large genome-wide association studies. Small sample size may have also affected the accuracy in estimating the contribution of the tested variants to the total phenotypic variance of measured gonadotropin concentrations. The group of eumenorrheic healthy women had its limitations as a control to estimate the true effect of analysed genetic variants on individual's fertility potential as the recruitment strategy had been targeted mostly towards younger women, who may not yet have planned to conceive a child by this age. WIDER IMPLICATIONS OF THE FINDINGS: We propose that like in men, also in women the FSHB -211 G>T represents a key genetic modulator of circulating gonadotropin, leading to various possible downstream effects on reproductive physiology. This claim is strongly supported by the reports of genome-wide association studies on various female reproductive traits and diseases. In perspective, FSHB -211 G>T may have a diagnostic value in fertility clinics to detect female patients with genetically inherited elevated basal FSH and LH levels. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by Estonian Science Foundation Grant (ETF9030 for M.L.); Institutional Research Grant (IUT34-12 for M.L.) and European Union through the European Regional Development Fund (project HAPPY PREGNANCY, 3.2.0701.12-0047; for M.L. and K.R.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the article. We have no competing interests to declare. TRAIL REGISTRATION NUMBER: Not applicable.
引用
- Rull K, Grigorova M, Ehrenberg A, et al. FSHB -211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women. Hum Reprod. 2018. PMID: 29617818. doi:10.1093/humrep/dey057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。